Project cooperationUpdated on 31 May 2026

CortexView Imaging Intelligence™ – AI-Enhanced Acquisition and Diagnosis

Head of Research and Innovation at Nowocert

Dublin, Ireland

About

CortexView Imaging Intelligence™ – AI-Enhanced Acquisition and Diagnosis

CortexView Imaging Intelligence™ enhances brain and multi-modal imaging from scan setup to final report by guiding protocol selection, enhancing image clarity, and ensuring consistent measurements. It helps technologists capture reliable scans with fewer repeats through real-time quality checks during acquisition, then supports radiologists with clear overlays and structured measurements that are easy to verify. The platform seamlessly integrates into radiology workflows, enabling teams to transition from acquisition to diagnosis more efficiently, with consistent performance across scanners and sites.

Key features include:

Smart acquisition guidance: Protocol recommendations and real-time quality checks to reduce repeats and standardize scans.
Clearer images with efficient reconstruction: Improved clarity and reduced noise to support faster scans while preserving diagnostic value.
Evidence-based clinical analytics: Readable overlays, measurements, and structured report drafts designed to work smoothly with PACS workflows.

Topic

IHI Topic 1: IHI European healthcare incubator network
IHI Topic 2: An AI foundation toxicology model and framework to support waiving a second species in drug safety studies
IHI Topic 3: Decode the immuno-science of age-related mediated diseases
HORIZON-MISS-2026-02-CANCER-01: Virtual Human Twin (VHT) Models for Cancer Research (RIA)
HORIZON-MISS-2026-02-CANCER-02: Microbiome for early cancer prediction before the onset of disease (RIA)
HORIZON-MISS-2026-02-CANCER-03: Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers (RIA)
HORIZON-MISS-2026-02-CANCER-04: Earlier and more precise palliative care (RIA)
HORIZON-MISS-2026-02-CANCER-05: Boosting mental health of young cancer survivors through the European Cancer Patient Digital Centre (ECPDC) (IA)
HORIZON-MISS-2026-02-CANCER-06: Development of a research capacity building programme on cancer with and for Ukraine (RIA)
HORIZON-MISS-2026-02-CANCER-07: Improve the Quality of Life of older cancer patients (RIA)
HORIZON_MISS-2027-02-CANCER-01 Leveraging functional genomics to reveal novel targets for cancer treatment
HORIZON_MISS-2027-02-CANCER-02 Clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers
HORIZON_MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
HORIZON_MISS-2027-02-CANCER-04 Improving equitable health outcomes and added value for and with cancer patients through health-economics research, health systems research and outcomes research
HORIZON_MISS-2027-02-CANCER-05 Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
HORIZON_MISS-2027-02-CANCER-06 Support a Young Cancer Survivor Quality of Life (QoL) research programme by cancer charities and funding agencies

Type

Partner offering expertise and is looking for a consortium

Organisation

Nowocert

Company (SME)

Dublin, Ireland

Similar opportunities

Project cooperation
PanGI Landmark Graph™ – Whole-Tract Capsule Intelligence
- IHI Topic 1: IHI European healthcare incubator network
- Partner offering expertise and is looking for a consortium
- IHI Topic 3: Decode the immuno-science of age-related mediated diseases
- HORIZON-MISS-2026-02-CANCER-04: Earlier and more precise palliative care (RIA)
- HORIZON-MISS-2026-02-CANCER-01: Virtual Human Twin (VHT) Models for Cancer Research (RIA)
- HORIZON-MISS-2026-02-CANCER-07: Improve the Quality of Life of older cancer patients (RIA)
- HORIZON-MISS-2026-02-CANCER-02: Microbiome for early cancer prediction before the onset of disease (RIA)
- HORIZON_MISS-2027-02-CANCER-01 Leveraging functional genomics to reveal novel targets for cancer treatment
- IHI Topic 2: An AI foundation toxicology model and framework to support waiving a second species in drug safety studies
- HORIZON-MISS-2026-02-CANCER-06: Development of a research capacity building programme on cancer with and for Ukraine (RIA)
- HORIZON_MISS-2027-02-CANCER-02 Clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers
- HORIZON-MISS-2026-02-CANCER-03: Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers (RIA)
- HORIZON-MISS-2026-02-CANCER-05: Boosting mental health of young cancer survivors through the European Cancer Patient Digital Centre (ECPDC) (IA)
- HORIZON_MISS-2027-02-CANCER-06 Support a Young Cancer Survivor Quality of Life (QoL) research programme by cancer charities and funding agencies
- HORIZON_MISS-2027-02-CANCER-05 Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
- HORIZON_MISS-2027-02-CANCER-04 Improving equitable health outcomes and added value for and with cancer patients through health-economics research, health systems research and outcomes research
- HORIZON_MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
Miadreza Shafiekhah
Head of Research and Innovation at Nowocert
Dublin, Ireland
Project cooperation
Digital Health & AI/ML SME | Real-World Data, Interoperability & Clinical AI Expertise Seeking CARMEN2026 Looking for a consortium to join with Widening Option
- IHI Topic 1: IHI European healthcare incubator network
- Partner offering expertise and is looking for a consortium
- IHI Topic 3: Decode the immuno-science of age-related mediated diseases
- HORIZON-MISS-2026-02-CANCER-04: Earlier and more precise palliative care (RIA)
- HORIZON-MISS-2026-02-CANCER-01: Virtual Human Twin (VHT) Models for Cancer Research (RIA)
- HORIZON-MISS-2026-02-CANCER-07: Improve the Quality of Life of older cancer patients (RIA)
- HORIZON-MISS-2026-02-CANCER-02: Microbiome for early cancer prediction before the onset of disease (RIA)
- HORIZON_MISS-2027-02-CANCER-01 Leveraging functional genomics to reveal novel targets for cancer treatment
- IHI Topic 2: An AI foundation toxicology model and framework to support waiving a second species in drug safety studies
- HORIZON-MISS-2026-02-CANCER-06: Development of a research capacity building programme on cancer with and for Ukraine (RIA)
- HORIZON_MISS-2027-02-CANCER-02 Clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers
- HORIZON-MISS-2026-02-CANCER-03: Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers (RIA)
- HORIZON-MISS-2026-02-CANCER-05: Boosting mental health of young cancer survivors through the European Cancer Patient Digital Centre (ECPDC) (IA)
- HORIZON_MISS-2027-02-CANCER-06 Support a Young Cancer Survivor Quality of Life (QoL) research programme by cancer charities and funding agencies
- HORIZON_MISS-2027-02-CANCER-05 Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
- HORIZON_MISS-2027-02-CANCER-04 Improving equitable health outcomes and added value for and with cancer patients through health-economics research, health systems research and outcomes research
- HORIZON_MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
Elifnaz Unay Kılıç
EU Technology & Funds Manager at TİGA
Ankara, Türkiye
Project cooperation
MaternAI LiveCare™ – Continuous Lifestyle and Maternal Health Intelligence
- IHI Topic 1: IHI European healthcare incubator network
- Partner offering expertise and is looking for a consortium
- IHI Topic 3: Decode the immuno-science of age-related mediated diseases
- HORIZON-MISS-2026-02-CANCER-04: Earlier and more precise palliative care (RIA)
- HORIZON-MISS-2026-02-CANCER-01: Virtual Human Twin (VHT) Models for Cancer Research (RIA)
- HORIZON-MISS-2026-02-CANCER-07: Improve the Quality of Life of older cancer patients (RIA)
- HORIZON-MISS-2026-02-CANCER-02: Microbiome for early cancer prediction before the onset of disease (RIA)
- HORIZON_MISS-2027-02-CANCER-01 Leveraging functional genomics to reveal novel targets for cancer treatment
- IHI Topic 2: An AI foundation toxicology model and framework to support waiving a second species in drug safety studies
- HORIZON-MISS-2026-02-CANCER-06: Development of a research capacity building programme on cancer with and for Ukraine (RIA)
- HORIZON_MISS-2027-02-CANCER-02 Clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers
- HORIZON-MISS-2026-02-CANCER-03: Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers (RIA)
- HORIZON-MISS-2026-02-CANCER-05: Boosting mental health of young cancer survivors through the European Cancer Patient Digital Centre (ECPDC) (IA)
- HORIZON_MISS-2027-02-CANCER-06 Support a Young Cancer Survivor Quality of Life (QoL) research programme by cancer charities and funding agencies
- HORIZON_MISS-2027-02-CANCER-05 Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
- HORIZON_MISS-2027-02-CANCER-04 Improving equitable health outcomes and added value for and with cancer patients through health-economics research, health systems research and outcomes research
- HORIZON_MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
Miadreza Shafiekhah
Head of Research and Innovation at Nowocert
Dublin, Ireland